DBV Tech Gets Requested Feedback from FDA on Comfort Safety Studies
By Stephen Nakrosis
DBV Technologies said it received requested feedback from the U.S. Food and Drug Administration for a pair of supplemental safety studies looking at its ViaSkin peanut allergy treatment.
The Characterization of the Optimal Management of Food Allergy Relief and Treatment, or Comfort, studies, will look at DBV's ViaSkin patches in children age 1 to 3 years old and in children age 4 to 7 years, the company said.
DBV said it has received FDA feedback clarifying design elements for both the Comfort Toddlers and Comfort Children supplemental safety studies. Both studies will have harmonized language guiding how the product will be used in the trials, and will "seek to enroll populations that are closely aligned with their respective Phase 3 efficacy studies, as is feasible," DBV said.
The company will implement FDA feedback, it said, adding that a submission of the final Comfort Toddlers protocol design will go to the FDA in the coming weeks. DBV also said it expects the first subject will be enrolled in the first quarter of next year.
The initiation of Comfort Children is expected after the start of Comfort Toddlers, DBV said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 31, 2023 18:33 ET (22:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom